Pluri 5/9/2024 Earnings Report

Pluri EPS Results

• Actual EPS: -$1.01
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Pluri Revenue Results

• Actual Revenue: $0.07 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Pluri Announcement Details

• Date: 5/9/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company dedicated to the development, manufacturing and commercialization of off-the-shelf cell therapy products based on proprietary placental-expanded (PLX) cell lines. Leveraging a three-dimensional cell expansion platform, the company generates PLX cells—mesenchymal-like cells derived from full-term placenta—which exhibit immunomodulatory, pro-angiogenic and anti-inflammatory properties. Pluri’s pipeline includes PLX-PAD for the treatment of critical limb ischemia, muscle regeneration and orthopedic conditions; PLX-R18 targeting hematopoietic recovery following radiation exposure; and PLX-COVID-19 for acute respiratory distress syndrome associated with viral infections.

Headquartered in Haifa, Israel, with additional operations in the United States, Pluri operates a fully integrated, cGMP-compliant manufacturing facility capable of producing large-scale cell therapy batches in bioreactors of up to 60,000 liters. This scalable infrastructure underpins the company’s strategy to advance multiple clinical programs in parallel, including ongoing Phase II and Phase III studies across North America and Europe. Pluri has established strategic collaborations with governmental agencies, research institutions and industry partners to support accelerated development through regulatory pathways such as the U.S. FDA’s regenerative medicine advanced therapy (RMAT) designation.

Founded in 2001, the company completed its initial public offering on the Nasdaq under the ticker PLUR in early 2024 following the merger of Pluristem Therapeutics and Pluri Biotechnology. Under the leadership of Chief Executive Officer Tal Vaks, Pluri is focused on translating its platform technology into safe, scalable therapies addressing unmet medical needs in cardiovascular, hematological and respiratory indications. With a multicultural team of scientists and industry veterans, Pluri aims to deliver affordable, off-the-shelf cell therapies that can be shipped directly to treatment centers worldwide.